Pfizer, Inc. (PFE)
$18.36
0.25 (+1.38%)
| CAPS Rating |
|
|---|---|
| Open | $18.15 |
| Previous Close | $18.11 |
| Daily Range | $18.12 - $18.48 |
| 52-Week Range | $11.62 - $18.48 |
| Market Cap | $148.16B |
| P/E Ratio | 15.09 |
| Dividend (Yield) | 0.64 (3.50%) |
| Volume | 60,967,250 |
| Average Daily Volume | 61,301,000 |
PFE
VS S&P 500 (SPY)
How do you think PFE will perform vs the S&P 500?
Caps
Motley Fool CAPS is a community working together to find better stocks and to become better investors.
PFE Advanced Details
- CAPS Community Analysis: Commentary, Scorecard
- Advanced Financial Analysis: Historical Prices, Chart, Stats, Ratios, Earnings/Growth Rates, Statements, SEC Filings
PFE News and Commentary
- Pfizer to pay $6.3 mln to patient in Prempro lawsuit – Reuters
- Taking Fido on Your Trip? There's a Drug for That. – The Motley Fool
- This Baby Is a Nice Addition – The Motley Fool
- US healthcare cos set for record lobbying in 2009 – Reuters
- 4-Star Stocks Poised to Pop: Merck – The Motley Fool
- Pfizer Executive:In Talks To Expand Licensing Pact With Aurobindo – SmartMoney
- The Easiest Money You'll Ever Make – The Motley Fool
- CORRECT:Justice Dept's Health-Care Fraud Caseload Nears 1,000 – SmartMoney
- Pfizer Dodges a Bullet – The Motley Fool
- UPDATE 1-US panel backs new claim for Pfizer lung drug – Reuters
- US Justice Dept: Health-Care Fraud Caseload Grows – SmartMoney
- The Only Way to Earn 50% Annual Returns – The Motley Fool
- Pfizer's Generic Growth, With a Side of Sashimi – The Motley Fool
- Abbott Hesitates To Promote Niaspan Study Due To FDA Rules – SmartMoney
- CORRECT: (11/18)FDA Board Considers Prevnar Vaccine Safe, Effective – SmartMoney
- UPDATE 3-U.S. Democrats demand analysis of drug price rises – Reuters
- In Search of Dividends...and More – SmartMoney
- FACTBOX-Winners, losers in U.S. Senate health bill – Reuters
- UPDATE 1-Pfizer says may enter Japan generic drug market – Reuters
- Pfizer to sell generic drugs in Japan - Nikkei – Reuters
RSS Headlines
Fool UK
